Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
Peter Schmid, Piotr Jan Wysocki, C.X. Ma, Y.H. Park, R. Fernandes, Simon Lord and 10 more
- Rank
- 69 of 3,639
- Percentile
- top 1.9%
- Where
- Annals of Oncology, 2023
- Citations
- 54
From the 2023 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.